Neuland Laboratories
Ticker > Company >

Neuland Laboratories share price

Neuland Laboratories Ltd.

NSE: NEULANDLAB BSE: 524558 SECTOR: Pharmaceuticals & Drugs  1.61 L   319   34

14398.10
-41.35 (-0.29%)
BSE: Today, 02:54 PM

Price Summary

Today's High

₹ 14545.4

Today's Low

₹ 14350

52 Week High

₹ 18089.55

52 Week Low

₹ 10060

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 18472.6 Cr.

Enterprise Value

₹ 18351.34 Cr.

No. of Shares

1.28 Cr.

P/E

105.68

P/B

12.07

Face Value

₹ 10

Div. Yield

0.08 %

Book Value (TTM)

₹  1192.99

CASH

₹ 257.27 Cr.

DEBT

₹ 136.01 Cr.

Promoter Holding

32.68 %

EPS (TTM)

₹  136.24

Sales Growth

-5.24%

ROE

18.58 %

ROCE

23.49%

Profit Growth

-13.41 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 24Indices.

NYMIDSML400MQ100

Nifty MidSmallcap400 Momentum Quality 100 Index
48007.5
  183.75 (0.384223320003141%)

NFTSML250MOMQ100

Nifty Smallcap250 Momentum Quality 100 index
45232.5
  185.150000000001 (0.411011968517583%)

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
44390
  114.25 (0.258041930402086%)

NIFTY500

Nifty 500
22946.9
  68.25 (0.298313056058808%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
19743.25
  32.4000000000015 (0.16437647285632%)

NIFTYSMALL

NIFTY Smallcap 100
17732.35
  48 (0.271426430714161%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
17636.5
  42.4500000000007 (0.241274749133935%)

NIFTYSMALLCAP250

Nifty Smallcap 250
16978.95
  43.7999999999993 (0.258633670206643%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
15990.8
  42.9499999999989 (0.269315299554473%)

NY500MUL50:30:20

Nifty500 Multicap India Manufacturing 50:30:20
15581.45
  19.3500000000004 (0.124340545299151%)

NFT500EQUAL

Nifty 500 Equal Weight
14263.8
  21.2999999999993 (0.149552395997898%)

NIFTYTOTALMCAP

Nifty Total Market index
12918.15
  37.6499999999996 (0.292302317456627%)

NIFTYSMALLCAP50

Nifty Smallcap 50
8522.4
  21.4499999999989 (0.252324740176091%)

SHARIAH500

Nifty500 Shariah
7112.4
  51.25 (0.725802454274449%)

SMLCAP

S&P Bse Small Cap
53006.94
  96.3100000000049 (0.182023914665175%)

BSE HC

S&P Bse Healthcare
44332.98
  205.910000000003 (0.466629667458096%)

BSE500MOM50

BSE 500 Momentum 50
42667.27
  221.459999999999 (0.521747611837298%)

BSE500

S&P Bse 500
36008.85
  92.6599999999962 (0.257989502784106%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
11963.68
  18.4600000000009 (0.154538802968895%)

BSE1000

Bse 1000
10733.19
  26.8999999999996 (0.251254169278048%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SHA500

S&P Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

SML250

S&P Bse 250 SmallCap
6793.53
  18.21 (0.268769593170504%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-5.24%
3 Year15.8%
5 Year14.13%

Profit Growth

1 Year-13.41%
3 Year59.83%
5 Year74.84%

ROE%

1 Year18.58%
3 Year20.99%
5 Year16.33%

ROCE %

1 Year23.49%
3 Year26.04%
5 Year20.08%

Debt/Equity

0.0897

Price to Cash Flow

58.18

Interest Cover Ratio

42.6318

CFO/PAT (5 Yr. Avg.)

1.23071885590375

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 32.68 0.00
Mar 2025 32.68 0.00
Dec 2024 32.68 0.00
Sep 2024 32.64 0.00
Jun 2024 32.72 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 59.8343549108334% for the Past 3 years.
  • The company has shown a good revenue growth of 15.7990726989542% for the Past 3 years.
  • Company has been maintaining healthy ROE of 20.9870666666667% over the past 3 years.
  • Company has been maintaining healthy ROCE of 26.0354666666667% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 42.6318.
  • The Company has been maintaining an effective average operating margins of 20.9636164739014% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 33.4604 days.
  • Company has a healthy liquidity position with current ratio of 2.4064.
  • The company has a good cash flow management; CFO/PAT stands at 1.23071885590375.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.66361051627282.

 Limitations

  • The company is trading at a high PE of 105.68.
  • The company is trading at a high EV/EBITDA of 71.4509.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 439.6 310.84 398.03 328.36 292.75
Total Expenditure 315.78 249.5 311.66 277.61 258.46
Operating Profit 123.83 61.34 86.38 50.75 34.29
Other Income 4.81 4.33 3.91 7.46 7.86
Interest 2.67 1.06 2.22 2.35 4.58
Depreciation 16.28 16.07 16.3 16.89 20.19
Exceptional Items 20.63 0 55.78 0 0
Profit Before Tax 130.31 48.54 127.55 38.98 17.38
Tax 31.97 16.58 26.15 11.25 3.67
Profit After Tax 98.34 31.96 101.39 27.73 13.71
Adjusted EPS (Rs) 76.23 24.77 78.59 21.5 10.63

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 936.91 951.08 1191.2 1558.58 1476.84
Total Expenditure 790.47 808.88 919.89 1096.66 1154.54
Operating Profit 146.44 142.19 271.31 461.92 322.3
Other Income 16.09 2.08 9.75 12.54 20.51
Interest 17.9 13.49 13.07 14 8.3
Depreciation 39.68 49.04 52.78 59.7 65.54
Exceptional Items 0 0 0 0 76.4
Profit Before Tax 104.96 81.74 215.21 400.77 345.37
Tax 24.67 18.21 52.09 101.17 85.95
Net Profit 80.29 63.53 163.12 299.6 259.43
Adjusted EPS (Rs.) 62.58 49.52 127.14 233.51 202.2

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 12.9 12.9 12.9 12.9 12.9
Total Reserves 768.98 822.67 975.46 1263.64 1504.89
Borrowings 88.13 104.25 74.25 44.92 90.73
Other N/C liabilities 80.54 74.17 70.98 75.67 96.82
Current liabilities 372.96 368.13 445.75 433.8 472.84
Total Liabilities 1323.52 1382.12 1579.34 1830.93 2178.17
Assets
Net Block 696.92 747.7 738.19 804.63 954.89
Capital WIP 17.25 20.46 40.57 45.89 44.55
Intangible WIP 0 0 0 0 3.11
Investments 0.6 0.66 0.68 1.44 1.69
Loans & Advances 41.66 14.4 20.21 40.31 35.88
Other N/C Assets 18.91 19.66 19.34 19.19 0.23
Current Assets 548.18 579.25 760.34 919.47 1137.82
Total Assets 1323.52 1382.12 1579.34 1830.93 2178.17
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 104.96 81.74 215.21 400.77 345.37
Adjustment 40.17 66.18 77.93 62.07 -12.01
Changes in Assets & Liabilities 49.34 -66.99 -11.04 -91.22 58.75
Tax Paid -5.19 -20.53 -43.57 -111.57 -74.62
Operating Cash Flow 189.28 60.41 238.53 260.06 317.49
Investing Cash Flow -84.42 -95.53 -61.5 -149.67 -298.14
Financing Cash Flow -113.66 37.72 -135.8 -69.28 24.96
Net Cash Flow -8.8 2.6 41.24 41.11 44.31

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 32.72 32.64 32.68 32.68 32.68
davuluri ownership trust ... - - - - 25.98
davuluri rohini niveditha... 0.67 0.67 0.67 0.67 0.67
davuluri saharsh rao 2.24 2.24 2.24 1.62 1.62
davuluri sucheth rao 2.63 2.63 2.63 2.01 2.01
davuluri vijaya rao 4.78 4.78 4.78 0.04 0.04
gannabathula uma bala 0.05 0.05 0.05 0.05 0.05
gannabathula veeravenkata... 0.17 0.17 0.17 0.17 0.17
gannabathula venkata kris... 0.27 0.25 0.25 0.25 0.25
ramamohan rao davuluri 21.59 21.59 21.63 1.63 1.63
usha rani reddy chevalla 0.32 0.27 0.27 0.26 0.26
davuluri ownership trust - - - 25.98 -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 67.28 67.36 67.32 67.32 67.32
hsbc balanced advantage f... - - 3.06 - 2.39
icici prudential s&p bse ... - - - - 1.78
investor education and pr... - - - 0.35 0.35
jupiter india fund 1.12 1.12 1.33 1.29 1.29
kedia securities private ... 1.09 1.01 1.01 1.01 1.01
malabar india fund limite... 8.86 6.08 5.76 5.76 5.76
matthews india fund 1.68 1.76 1.76 1.31 1.04
mukul mahavir agrawal 3.12 3.12 3.12 3.12 3.12
siddharth iyer 1.49 1.69 1.73 1.62 1.62
hsbc focused fund - - - 2.92 -
icici prudential flexicap... - - - 1.33 -
investor education and pr... 0.37 0.24 0.36 - -
hsbc small cap fund - 2.56 - - -
smallcap world fund, inc 1.08 3.77 - - -
hsbc multi cap fund 2.71 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit FITCH
Credit FITCH
Credit CRISIL
Credit FITCH
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
Research BP Wealth

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY22
Concall Q3FY24
Concall Q3FY23
Concall Q2FY23
Concall Q1FY24
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q3FY24
Presentation Q3FY21
Presentation Q2FY24
Presentation Q2FY21
Presentation Q1FY26
Presentation Q1FY22
Presentation Q1FY21

Company News

Neuland Laboratories informs about newspaper advertisement 3 Sep, 10:17 AM Neuland Laboratories informs about loss of share certificate 12 Aug, 4:39 PM Neuland Laboratories informs about newspaper publication 1 Aug, 12:49 PM Neuland Laboratories - Quaterly Results 31 Jul, 4:21 PM Neuland Laboratories - Quaterly Results 31 Jul, 4:21 PM Neuland Laboratories - Quaterly Results 31 Jul, 4:21 PM Neuland Laboratories informs about newspaper advertisement 5 Jul, 2:21 PM Neuland Laboratories informs about credit rating 21 Jun, 10:09 AM Neuland Laboratories informs about newspaper advertisement 17 Jun, 1:07 PM Neuland Laboratories informs about newspaper advertisement 17 Jun, 12:06 PM Neuland Laboratories informs about issuance of letter of confirmation 17 Jun, 11:32 AM Neuland Laboratories informs about analyst meet 11 Jun, 2:30 PM Neuland Laboratories approves dividend 16 May, 12:37 PM Neuland Laboratories informs about newspaper advertisement 16 May, 12:28 PM Neuland Laboratories informs about newspaper advertisement 16 May, 10:54 AM Neuland Laboratories - Quaterly Results 15 May, 4:13 PM Neuland Laboratories - Quaterly Results 15 May, 4:13 PM Neuland Laboratories - Quaterly Results 15 May, 4:13 PM Neuland Laboratories informs about earnings call 5 May, 10:53 AM USFDA inspects Neuland Laboratories’ Unit 2 manufacturing facility in Telangana 3 May, 4:22 PM Neuland Laboratories informs about board meeting 24 Apr, 4:53 PM Neuland Laboratories informs about disclosure 27 Feb, 3:07 PM Neuland Laboratories informs about disclosure 25 Feb, 11:48 AM Neuland Laboratories - Quaterly Results 10 Feb, 4:27 PM Neuland Laboratories - Quaterly Results 10 Feb, 4:27 PM Neuland Laboratories - Quaterly Results 10 Feb, 4:27 PM Neuland Laboratories informs about certificate 3 Jan, 10:24 AM Neuland Laboratories informs about updates 24 Dec, 5:09 PM Neuland Laboratories informs about disclosure 13 Dec, 3:44 PM Neuland Laboratories informs about disclosure 29 Nov, 3:41 PM Neuland Laboratories informs about investor meet 20 Nov, 12:54 PM Neuland Laboratories informs about newspaper advertisement 7 Nov, 1:08 PM Neuland Laboratories informs about press release 6 Nov, 5:48 PM Neuland Laboratories - Quaterly Results 6 Nov, 1:11 PM Neuland Laboratories - Quaterly Results 6 Nov, 1:11 PM Neuland Laboratories - Quaterly Results 6 Nov, 1:11 PM Neuland Laboratories informs about certificate 15 Oct, 2:16 PM Neuland Laboratories informs about details of loss of certificate 9 Oct, 4:58 PM Neuland Laboratories informs about analyst presentation 1 Aug, 5:25 PM Neuland Laboratories - Quaterly Results 1 Aug, 3:20 PM Neuland Laboratories - Quaterly Results 1 Aug, 3:20 PM Neuland Laboratories - Quaterly Results 1 Aug, 3:20 PM Neuland Laboratories informs about earnings call 24 Jul, 12:44 PM Neuland Laboratories informs about loss of share certificate 21 Jun, 12:26 PM Neuland Laboratories informs about investor meet 18 Jun, 1:02 PM Neuland Laboratories informs about press release 10 Jun, 2:43 PM Neuland Laboratories informs about loss of share certificates 3 Jun, 5:09 PM Neuland Laboratories informs about loss of share certificate 31 May, 5:27 PM Neuland Laboratories submits compliance certificate 24 May, 10:54 AM Neuland Laboratories - Quaterly Results 10 May, 4:16 PM

Neuland Laboratories Stock Price Analysis and Quick Research Report. Is Neuland Laboratories an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Neuland Laboratories. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Neuland Laboratories has a PE ratio of 106.055101089617 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Neuland Laboratories has ROA of 12.9418% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Neuland Laboratories has a Current ratio of 2.4064.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Neuland Laboratories has a ROE of 18.5801%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Neuland Laboratories has a Debt to Equity ratio of 0.0897 which means that the company has low proportion of debt in its capital.

  • Sales growth: Neuland Laboratories has reported revenue growth of -5.2447% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Neuland Laboratories for the current financial year is 21.8235888272865%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Neuland Laboratories is Rs 12 and the yield is 0.0833%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Neuland Laboratories is Rs 136.2405. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Neuland Laboratories in Ticker for free. Also, one can get the intrinsic value of Neuland Laboratories by using Valuation Calculators, which are available with a Finology ONE subscription. 

Neuland Laboratories FAQs

Q1. What is Neuland Laboratories share price today?
Ans: The current share price of Neuland Laboratories is Rs 14449.

Q2. What is the market capitalisation of Neuland Laboratories?
Ans: Neuland Laboratories has a market capitalisation of Rs 18537.9066161 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Neuland Laboratories?
Ans: The PE ratio of Neuland Laboratories is 106.055101089617 and the P/B ratio of Neuland Laboratories is 12.1116156336993, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Neuland Laboratories share?
Ans: The 52-week high share price of Neuland Laboratories is Rs 18100, and the 52-week low share price of Neuland Laboratories is Rs 10190.7.

Q5. Does Neuland Laboratories pay dividends?
Ans: Currently, Neuland Laboratories pays dividends. Dividend yield of Neuland Laboratories is around 0.0833%.

Q6. What are the face value and book value of Neuland Laboratories shares?
Ans: The face value of Neuland Laboratories shares is Rs 10, while the book value per share of Neuland Laboratories is around Rs 1192.987. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Neuland Laboratories?
Ans: Neuland Laboratories has a total debt of Rs 136.0101 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Neuland Laboratories?
Ans: The ROE of Neuland Laboratories is 18.5801% and ROCE of Neuland Laboratories is 23.4905%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Neuland Laboratories a good buy for the long term?
Ans: The Neuland Laboratories long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Neuland Laboratories undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Neuland Laboratories appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Neuland Laboratories’s financials?
Ans: You can review Neuland Laboratories’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Neuland Laboratories

Neuland Laboratories Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Neuland Laboratories Ltd. is a renowned pharmaceutical company that specializes in the manufacture and supply of Active Pharmaceutical Ingredients (APIs) and intermediates. With a rich heritage spanning over three decades, Neuland has emerged as a trusted name in the global pharmaceutical industry.

Neuland Laboratories Ltd. - Share Price

Stay updated with the latest Neuland Laboratories Ltd. share price on our website. Our pre-built screening tools enable you to track the performance of Neuland's stock and monitor any fluctuations in the share price.

Neuland Laboratories Ltd. - Balance Sheet

Access Neuland Laboratories Ltd.'s balance sheet on our website. Our premium features allow you to perform fair value calculations using tools such as DCF Analysis, BVPS Analysis, Earnings Multiple Approach, and DuPont Analysis. These analytical tools provide insights into the financial health and stability of the company.

Neuland Laboratories Ltd. - Annual Report

Downloadable annual reports of Neuland Laboratories Ltd. are available on our website. These reports offer a comprehensive overview of the company's performance, achievements, and future plans. Analyzing the annual report can assist long-term stock investors in making informed decisions.

Neuland Laboratories Ltd. - Dividend

Stay informed about Neuland Laboratories Ltd.'s dividend payouts on our website. Dividends are a significant consideration for long-term investors, and our platform provides detailed information on the company's dividend history and payout ratios.

Neuland Laboratories Ltd. - Quarterly Result

Monitor the quarterly financial performance of Neuland Laboratories Ltd. by accessing the latest results on our website. Use our pre-built screening tools to analyze the company's financial statements and track key metrics. These insights can guide long-term investors in assessing the company's growth trajectory.

Neuland Laboratories Ltd. - Stock Price

Neuland Laboratories Ltd.'s stock price plays a crucial role in investment decisions. Stay up-to-date with the current stock price and historical trends on our website. Our price charts enable long-term investors to analyze patterns and identify potential buying or selling opportunities.

Neuland Laboratories Ltd. - Price Chart

Visualize Neuland Laboratories Ltd.'s stock price trends through our interactive price charts. These charts are designed to assist long-term investors in identifying patterns, trends, and potential entry or exit points.

Neuland Laboratories Ltd. - News

Access the latest news and updates about Neuland Laboratories Ltd. on our website. Stay informed about the company's developments, collaborations, regulatory approvals, and other significant events that may impact its stock performance.

Neuland Laboratories Ltd. - Concall Transcripts

Download the concall transcripts of Neuland Laboratories Ltd. from our website. Concall transcripts provide insights into management discussions, future plans, and strategic decisions. Analyzing these transcripts can aid long-term investors in understanding the company's outlook and prospects.

Neuland Laboratories Ltd. - Investor Presentations

Explore the investor presentations of Neuland Laboratories Ltd. on our website. These presentations provide a comprehensive overview of the company's operations, financial performance, and growth strategies. Reviewing these presentations can be valuable for long-term investors seeking in-depth insights.

Neuland Laboratories Ltd. - Promoters

Neuland Laboratories Ltd. is backed by a strong team of promoters who bring extensive expertise and industry knowledge to the company. The promoters' vision and strategic direction play a pivotal role in shaping Neuland's growth and success.

Neuland Laboratories Ltd. - Shareholders

Stay informed about Neuland Laboratories Ltd.'s shareholders on our website. Understanding the company's ownership structure can provide insights into the level of institutional investment and the overall market sentiment towards the stock.

At our website, we strive to provide comprehensive stock analysis and valuable tools to assist long-term investors in making informed decisions. Take advantage of our pre-built screening tools, downloadable reports, and premium features to enhance your investment research process. Happy investing! 

Neuland Laboratories Balance Sheet Examination

Neuland Laboratories Share Capital Unchanged

Throughout the span from March 2020 to March 2024, Neuland Laboratories has maintained its share capital consistently at Rs Cr. 12.90, reinforcing a stable equity base.

Neuland Laboratories Reserves on the Rise

A significant uptick in total reserves from Rs Cr. 692.64 in March 2020 to Rs Cr. 1,263.64 in March 2024 showcases Neuland Laboratories' bolstered financial resilience and profit retention capability.

Neuland Laboratories Debt Reduction

The borrowing profile of Neuland Laboratories shows a commendable decrease to Rs Cr. 44.92 by March 2024 from Rs Cr. 77.37 in March 2020, reflecting a prudent debt management strategy.

Neuland Laboratories Assets Growth

The asset base has seen an upward trajectory, growing from Rs Cr. 1,229.74 in March 2020 to Rs Cr. 1,830.93 by March 2024. Notable growth in Net Block and Current Assets indicates strategic investments in operational efficiency and liquidity enhancement.

This analysis is based on the Standalone Balance sheet of Neuland Laboratories, shedding light on its financial health and strategic directions over the reviewed period.

Investors interested in the pharmaceutical sector might find Neuland Laboratories' financial progress and strategic investments in assets a focal point amidst evolving market dynamics.

Read More
X